LBA
TENX icon

Letko, Brosseau & Associates’s Tenax Therapeutics TENX Stock Holding History

Letko, Brosseau & Associates’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Hold
10,650
– – ﹤0.01% 107
2026
Q1 		$170K Hold
10,650
– – ﹤0.01% 94
2025
Q4 		$130K Buy
+10,650
New +$92.6K ﹤0.01% 94

Other funds holding TENX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Letko, Brosseau & Associates's TENX Position: Q2 2026 in Review

Letko, Brosseau & Associates held its Tenax Therapeutics (TENX) position steady in Q2 2026 at 10,650 shares worth $155K. The position accounts for ﹤0.01% of the portfolio, ranked #107.

Letko, Brosseau & Associates first reported a position in TENX in Q4 2025 and has held it in 3 quarters since. The position peaked at $170K in Q1 2026. 111 funds tracked by Wall St. Rank hold TENX as of Q2 2026.

  • Letko, Brosseau & Associates held 10,650 shares of Tenax Therapeutics worth $155K as of Q2 2026.
  • Letko, Brosseau & Associates left its Tenax Therapeutics share count unchanged in Q2 2026.
  • Tenax Therapeutics made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q2 2026, its #107 holding.
  • Letko, Brosseau & Associates first reported a position in Tenax Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Letko, Brosseau & Associates's Tenax Therapeutics position peaked at $170K in Q1 2026.
  • 111 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q2 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q2 2026, filed 13 Aug 2026.